Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness [Internet]

Excerpt

Intravenous immunoglobulin (IVIG) has been identified as a potentially beneficial therapy for patients experiencing solid organ transplant rejection. The purpose of this report is to provide a synthesis of the available evidence on the clinical effectiveness of off-label use of IVIG for solid organ transplant rejection. This report is complementary to a 2017 CADTH Rapid Response, Summary of Abstracts report: “Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness”